Key Highlights

  • BKHA shares trading up 9.17% today to $5.00.
  • The blank check company is set to combine with Vesicor Therapeutics at a $70 million Equity value.
  • BKHA closed at $4.29 on October 22, after a 12.45% fall that day.
  • About 2.12 million public shares remained outstanding, backed by roughly $22.7 million in trust, as of a July filing.
  • The combined company has applied to list on Nasdaq under the symbol VESI.

Black Hawk Shares Gain 9.17% as the Vesicor Deal Awaits Completion

Black Hawk Acquisition (NASDAQ:BKHA) shares are trading up 9.17% today at $5.00. No press release or filing dated today was identified that explains the move, and the stock has been volatile as the proposed Merger moves forward. Investors tracking the shares are mainly watching the Vesicor deal.

Black Hawk is a blank check company incorporated in 2023 and based in Danville, California. Its initial public offering priced at $10 per share on March 21, 2024, to fund a merger, share exchange, asset acquisition or similar Business combination. It has no operating business of its own.

The stock closed at $4.29 on October 22, 2026, a one-day decline of 12.45%, so today's level of $5.00 is a notable rebound from that mark.

Vesicor Therapeutics Merger Terms and the Planned VESI Listing

Under the proxy statement and prospectus, Vesicor shareholders would receive shares of the new parent company, with the total set by dividing a $70 million equity value by the Redemption price per Black Hawk Class A share. The parent would be renamed Vesicor Therapeutics Holdings and has applied to trade on Nasdaq as VESI. Vesicor warrants would convert into warrants on the parent company's stock.

Vesicor's sole product candidate is ecm-RV/p53. As of the July filing, the company had not begun preclinical or IND-enabling studies, had not filed an IND and had no FDA approval for any use.

The registration statement was declared effective on September 17, 2026, and an extraordinary general meeting on the business combination was reported as scheduled for October 13. The outcome of that vote and the closing status were not confirmed in the sources reviewed.

Trust Value, Redemptions and Going Concern Language Weigh on the Structure

The July filing showed a trust value of about $12.04 per public share, with roughly 2.12 million public shares still outstanding and about $22.7 million held in trust. Those figures can change as shareholders redeem ahead of a merger vote.

A third-party summary of the Quarterly Report said management included going concern language, citing a cash balance of about $12,052 and a Working Capital Deficit near $2.3 million. That summary was generated automatically and its figures should be checked against the filing itself.

The filing also required Vesicor to arrange a private Placement of at least $10 million before closing, and at the time neither company had entered into such an investment.

Closing Steps and Listing Approval Decide the Next Phase

Today's 9.17% advance leaves Black Hawk at $5.00, compared with the $10 price at its public offering. The merger is the central item for the shares, and the next steps include confirmation of the meeting result, satisfaction of the financing condition, Nasdaq approval for the VESI symbol, and the actual closing and domestication of the parent company. Redemption levels at closing will also determine how much cash remains in trust.